Alcobra Ltd  

(Public, NASDAQ:ADHD)   Watch this stock  
Find more results for David B. Rosen´┐Ż
4.16
-0.03 (-0.72%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.03 - 4.16
52 week 3.15 - 9.50
Open 4.15
Vol / Avg. 47,566.00/81,182.00
Mkt cap 111.46M
P/E     -
Div/yield     -
EPS -0.83
Shares 27.56M
Beta 1.31
Inst. own 78%
Jul 27, 2016
Q2 2016 Alcobra Ltd Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 12, 2016
Alcobra Ltd at Cantor Fitzgerald Healthcare Conference
Jun 22, 2016
Alcobra Ltd at ROTH Healthcare Day
Jun 7, 2016
Alcobra Ltd at Jefferies Healthcare Conference
May 22, 2016
Alcobra Ltd at Oppenheimer Israeli Conference
May 16, 2016
Q1 2016 Alcobra Ltd Earnings Release
May 16, 2016
Q1 2016 Alcobra Ltd Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -29.40% -41.38%
Return on average equity -30.38% -43.57%
Employees 19 -
CDP Score - -

Address

Azrieli Triangle Bldg Fl 39th, 132, Derekh Menakhem Begin
TEL AVIV-YAFO, 6701101
Israel
+972-7-22204661 (Phone)
+972-7-22204664 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Officers and directors

Howard B. Rosen Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Yaron Daniely President, Chief Executive Officer, Director
Age: 39
Bio & Compensation  - Reuters
Tomer Berkovitz Chief Financial Officer
Age: 35
Bio & Compensation  - Reuters
Hagit Marchaim Ph.D. Senior Vice President - Regulatory Affairs
Age: 46
Bio & Compensation  - Reuters
Hanna Ron Senior Vice President of Chemistry, Manufacturing and Control
Age: 64
Bio & Compensation  - Reuters
Oded Edri Vice President - Finance
Age: 36
Bio & Compensation  - Reuters
Johanna Schumann Vice President - Preclinical Development
Age: 34
Bio & Compensation  - Reuters
David C. Baker Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Jonathan Rubin M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Daniel E. Geffken CPA Director
Age: 58
Bio & Compensation  - Reuters